Khandoker Usran Ferdous

Researcher

UAMS

Also affiliated: University of Maryland, Baltimore (2026); North South University (2018–2020); Little Rock School District (2025); University of Arkansas Medical Center (2025); Winthrop Rockefeller Foundation (2024–2025)

Faculty Researcher

5 h-index 20 pubs 74 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Khandoker Usran Ferdous investigates the use of oncolytic viruses and other immunotherapies for cancer treatment. His research focuses on enhancing immune responses against various cancer types, including hepatocellular carcinoma and pancreatic cancer. Ferdous has explored repurposing existing vaccines, such as the MMR vaccine, as a cost-effective immunotherapy strategy. He also studies the effectiveness of novel oncolytic viruses, like the Jurona virus, in combination with immune checkpoint blockade to improve patient survival and tumor resectability. His work examines the mechanisms of resistance to oncolytic virotherapy and aims to reprogram the tumor microenvironment to achieve better therapeutic outcomes. Ferdous has a recent publication in 2026 and is actively engaged in research within the field of oncology and immunology.

Metrics

h-index: 5
Publications: 20
Citations: 74

Selected Publications

Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)

Cancer Research DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)

Cancer Research DOI OpenAlex
Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses (2025)

Frontiers in Immunology 12 citations DOI OpenAlex
Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment (2025)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
Abstract 950: Engineered oncolytic vesiculovirus downsizes pancreatic tumor and boosts immune response (2025)

Cancer Research DOI OpenAlex
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025)

Cancer Research DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

Cancer Research DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

Cancer Research DOI OpenAlex
Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma (2025)

Molecular Therapy Oncology 3 citations DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

Molecular Therapy Oncology 5 citations DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

Biomedicines 5 citations DOI OpenAlex
Abstract 588: Preclinical evaluation of novel chimeric vesiculovirus mediated expression of proteolytic enzymes targeting two major stromal components of pancreatic ductal adenocarcinoma (2024)

Cancer Research DOI OpenAlex
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)

Cancer Research DOI OpenAlex
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)

Frontiers in Oncology 7 citations DOI OpenAlex